Skip to main content
Clinical Trials/NCT01795612
NCT01795612
Completed
Not Applicable

Adapted Physical Activity Effect on Aerobic Function and Fatigue at Home in Patients With Breast Cancer Treated in Adjuvant or Neoadjuvant Phase

University Hospital, Limoges1 site in 1 country94 target enrollmentMarch 2013
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
University Hospital, Limoges
Enrollment
94
Locations
1
Primary Endpoint
The main criterion is exercise tolerance at 12 months measured by VO2peak by incremental cardiopulmonary exercise test
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Physical exercise has been identified as a major item of many chronic diseases and cancer rehabilitation. It contributes to an improvement in the quality of life and to a decrease in the current treatment side effects and mortality. Cancer in association with treatment toxicity and an inactive lifestyle lead to a fall in physical capability and causes problems in daily activities. The physical capacity and the tolerance for exercise fall simultaneously leading to a deconditioning vicious circle which increases physical, psychological and emotional symptoms of fatigue. Therefore, physical activity for health is a valid and relevant way to improve quality of life and to manage cancer patient fatigue. The aim of the study is the assessment of the effects of a physical activity retraining program on aerobic capacity, strength and fatigue, in a breast cancer population treated by adjuvant or néoadjuvant chemotherapy.

Registry
clinicaltrials.gov
Start Date
March 2013
End Date
December 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
University Hospital, Limoges
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • females between 18 and 75 years of age;
  • signed written informed consent;
  • willing to take part in the trial and to follow the instructions;
  • breast tumour, histologically documented;
  • patients for whom a 6-treatment course of adjuvant or neoadjuvant chemotherapy (3FEC100 +3 taxanes or 6 FEC) +/- radiotherapy+/- Herceptin has been scheduled;

Exclusion Criteria

  • metastatic cancer;
  • disability preventing a proper understanding of the instructions for the trial;
  • patients who are subject to a court protection, wardship or guardianship order;
  • uncontrolled hypertension;
  • family history of sudden death in a first-degree relative;
  • unstabilised heart disease;
  • current treatment with beta-blockers;
  • chronic or acute pulmonary disease associated with dyspnoea upon moderate effort;
  • uncontrolled thyroid dysfunction;
  • uncontrolled diabetes;

Outcomes

Primary Outcomes

The main criterion is exercise tolerance at 12 months measured by VO2peak by incremental cardiopulmonary exercise test

Time Frame: at 12 months

unit of measure:ml/kg/min

Secondary Outcomes

  • Exercise tolerance at 12 months (group A vs B)(at 12 months)

Study Sites (1)

Loading locations...

Similar Trials